Propanc Biopharma, Inc.
PPCB evidence brief
What we can confirm
- BioSniper Score:
- 4.7 / 10
- Market Cap:
- $2.1M
- Lead Asset:
- prp (Preclinical)
What it means
What to watch
Prepared research question
What matters most for PPCB—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · PPCB
Propanc Biopharma, Inc. (PPCB) is a development-stage biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, with its lead candidate PRP advancing toward a Phase 1b first-in-human clinical trial.
Key risk: No approved products
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$2.1M
Cash Runway
—
Lead Asset
prp (Preclinical)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate for Propanc Biopharma, Inc..
Propanc Biopharma, Inc. (PPCB) is a development-stage biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, with its lead candidate PRP advancing toward a Phase 1b first-in-human clinical trial.
- Propanc is a development-stage healthcare company focused on developing new cancer treatments for pancreatic, ovarian and colorectal cancer [sec · filed 2026-04-10].
- Lead candidate PRP is advancing toward a Phase 1b first-in-human clinical trial expected in 2026 [news · published 2025-11-17].
- Shareholders' equity was $9.4M as of 2026-06-30 [latest reported financials].
- The company reported new preclinical and translational data for PRP in pancreatic ductal adenocarcinoma in August 2026 [news · published 2026-08-06].
- Propanc issued a comparative analysis of PRP against RAS-targeted programs including Revolution Medicines’ daraxonrasib and Erasca’s pan-RAS molecular glue in September 2026 [news · published 2026-09-16].
What works
- Propanc is advancing PRP toward a Phase 1b first-in-human trial, indicating progress in its development pipeline [news · published 2025-11-17].
- The company is generating preclinical and translational data for PRP in pancreatic ductal adenocarcinoma, a challenging cancer type [news · published 2026-08-06].
- Propanc is actively comparing its lead candidate against established RAS-targeted programs, suggesting a data-driven approach to differentiation [news · published 2026-09-16].
What to weigh
- Propanc is a development-stage company with no marketed products, and its ability to achieve profitable operations depends on future events including financing and regulatory approval [sec · filed 2026-04-10].
- The company's consolidated financial statements include a 'Going Concern Qualification' that may make it substantially more difficult to raise capital [sec · filed 2026-04-10].
- Propanc's forward-looking statements are subject to numerous uncertainties and risks, many beyond its control, and actual results could differ materially [sec_mda · as of 2026-05-14].
From the filings
Quoted directly from source documents.
Propanc is a development-stage company focused on cancer treatments.
“We are a development-stage healthcare company that is currently focused on developing new cancer treatments for patients suffering from pancreatic, ovarian and colorectal cancer.”
SEC MD&A · April 10, 2026
PRP is advancing toward a Phase 1b first-in-human trial in 2026.
“Advancing PRP Toward Phase 1b First-in-Human Trial (2026)”
News · November 17, 2025
Risks & what to watch (3)›
Key risks
- No approved products — Propanc has no marketed products and relies on future financing and regulatory success [sec · filed 2026-04-10].
- Going concern qualification — The 'Going Concern Qualification' may hinder capital raising efforts [sec · filed 2026-04-10].
- Forward-looking uncertainties — Actual results may differ materially from projections due to numerous risks [sec_mda · as of 2026-05-14].
What to watch
- Initiation and progress of the Phase 1b first-in-human trial for PRP, expected in 2026 [news · published 2025-11-17].
- Additional preclinical and translational data releases for PRP, particularly in pancreatic cancer [news · published 2026-08-06].
- Any updates on financing or capital raising, given the going concern qualification [sec · filed 2026-04-10].
- Comparative analyses of PRP against other RAS-targeted programs [news · published 2026-09-16].
Sources: News · SEC filings · SEC MD&A · Generated September 30, 2026 · How we verify sources →
Run Propanc Biopharma, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Propanc Biopharma, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.36
Lead: Preclinical
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Financials
Short Interest
as of May 22, 2026- % of float
- 3.3%
- Days to cover
- 0.1
- Shares short
- 20,951
- Daily short volume (May 6, 2026)
- 76.0%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
PPCB short interestFrequently asked questions
What is the AI investment thesis for Propanc Biopharma, Inc.?
Propanc Biopharma, Inc. (PPCB) is a development-stage biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, with its lead candidate PRP advancing toward a Phase 1b first-in-human clinical trial.
What is Propanc Biopharma, Inc.'s lead drug candidate?
Propanc Biopharma, Inc.'s most advanced tracked candidate is prp (Preclinical) for Pancreatic cancer.
Who is the CEO of Propanc Biopharma, Inc.?
Mr. James Nathanielsz is the chief executive officer of Propanc Biopharma, Inc. (PPCB).
Where is Propanc Biopharma, Inc. headquartered?
Propanc Biopharma, Inc. (PPCB) is headquartered in Camberwell, VIC, Australia.
What therapeutic areas does Propanc Biopharma, Inc. focus on?
Propanc Biopharma, Inc. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.